Lopinavir/ritonavir is an oral antiretroviral protease inhibitor combination agent under investigation for the treatment of COVID-19. Lopinavir/ritonavir is FDA approved for use in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults and pediatric patients aged 14 days and older.

If you have a Hayes login, click here to view the full report on the Knowledge Center.